Glimepiride
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Glimepiride: From Type 2 Diabetes Mellitus to Focal Stiff Limb Syndrome
One-Sentence Summary
Glimepiride is a third-generation sulfonylurea originally developed to treat type 2 diabetes mellitus. The TxGNN model assigns a very high prediction score (99.75%) to Focal Stiff Limb Syndrome as a potential new indication, but this candidate currently has zero clinical trials and zero publications supporting it, and the proposed biological rationale is considered weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 Diabetes Mellitus (established sulfonylurea use; no formal EU/TW marketing-authorization record on file) |
| Predicted New Indication | Focal Stiff Limb Syndrome |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data for glimepiride is not available in this evidence pack (flagged as a High-severity data gap — DG002). Based on known pharmacology, glimepiride is part of the sulfonylurea class, and its glucose-lowering efficacy in type 2 diabetes is well established through binding to the SUR1 subunit (ABCC8) of the pancreatic β-cell KATP channel, which triggers insulin release.
Focal Stiff Limb Syndrome, by contrast, belongs to the stiff-person syndrome spectrum, a disease driven by GAD65 autoantibody-mediated autoimmunity and impaired GABAergic neurotransmission in the central nervous system. According to the evidence pack’s own rationale, there is no known biological link between sulfonylurea-mediated KATP channel closure and GABAergic/autoimmune neurological dysfunction.
The model’s high similarity score is therefore assessed as most likely arising from knowledge-graph comorbidity patterns or drug-similarity artifacts rather than a genuine, testable pharmacological mechanism. This candidate should be treated as a low-confidence, exploratory signal rather than a mechanistically grounded hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
No marketing authorizations are on file for this jurisdiction — the evidence pack lists 0 licenses and a “Not Marketed” status. This is a Blocking-severity data gap (DG001: TFDA label/warnings and contraindications), which also prevents any Stage 1 safety review for this drug.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has no supporting clinical trials or literature (Evidence Level L5, Decision Stage S0), and the proposed mechanistic link to sulfonylurea pharmacology is not biologically plausible — the evidence pack itself flags the prediction as a likely knowledge-graph artifact rather than a genuine signal.
To proceed, the following is needed:
- TFDA-approved label data (warnings, contraindications) — currently a Blocking data gap (DG001)
- Confirmed mechanism-of-action data from DrugBank (DG002) to properly assess mechanistic plausibility
- Independent preclinical or mechanistic evidence linking sulfonylurea/KATP-channel activity to autoimmune/GABAergic pathology before any further investment
Note: Within the same evidence pack, a different candidate for glimepiride — type 1 diabetes mellitus (rank 10, score 98.86%) — has materially stronger support (Evidence Level L3, 50 clinical trials, 17 publications, decision stage S1 “Research Question”) and may warrant a separate, dedicated evaluation report rather than being pursued under this Hold decision.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.